Urokinase perfusion prevents intrahepatic ischemic-type biliary lesion in donor livers.
OBJECTIVE
To evaluate whether urokinase perfusion of non-heart-beating cadaveric donor livers reduces the incidence of intrahepatic ischemic-type biliary lesions (IITBLs).


METHODS
A prospective study was conducted to investigate potential microthrombosis in biliary microcirculation when non-heart-beating cadaveric livers were under warm or cold ischemic conditions. The experimental group included 140 patients who underwent liver transplantation during the period of January 2006 to December 2007, and survived for more than 1 year. The control group included 220 patients who received liver transplantation between July 1999 and December 2005 and survived for more than 1 year. In the experimental group, the arterial system of the donor liver was perfused twice with urokinase during cold perfusion and after trimming of the donor liver. The incidence of IITBLs was compared between the two groups.


RESULTS
In the control group, the incidence of IITBLs was 5.9% (13/220 cases) after 3-11 mo of transplantation. In the experimental group, two recipients (1.4%) developed IITBLs at 3 and 6 mo after transplantation, respectively. The difference in the incidence between the two groups was statistically significant (P < 0.05).


CONCLUSIONS
Double perfusion of cadaveric livers from non-heart-beating donors with urokinase may reduce the incidence of IITBLs.
Lang
Ren
R
Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing Center for Organ Transplantation, Beijing 100020, China.
He
Qiang
Q
Jin
Zhong-Kui
ZK
Han
Dong-Dong
DD
Chen
Da-Zhi
DZ
D000293:Adolescent; D000328:Adult; D000368:Aged; D002102:Cadaver; D005260:Female; D006801:Humans; D008099:Liver / Q000098:blood supply / Q000473:pathology*; D016031:Liver Transplantation / Q000009:adverse effects / Q000379:methods; D008297:Male; D008875:Middle Aged; D019188:Organ Preservation Solutions / Q000737:chemistry*; D010477:Perfusion; D011446:Prospective Studies; D014019:Tissue Donors; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage* / Q000378:metabolism; D055815:Young Adult
D019188:Organ Preservation Solutions; D014568:Urokinase-Type Plasminogen Activator